Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions
- PMID: 27417001
- PMCID: PMC6278927
- DOI: 10.1016/j.jacc.2016.05.013
Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions
Keywords: heart failure; outcomes; readmission; valsartan/sacubitril.
Comment on
-
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.J Am Coll Cardiol. 2016 Jul 19;68(3):241-248. doi: 10.1016/j.jacc.2016.04.047. J Am Coll Cardiol. 2016. PMID: 27417000 Clinical Trial.
Similar articles
-
Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.ESC Heart Fail. 2018 Apr;5(2):327-336. doi: 10.1002/ehf2.12246. Epub 2017 Dec 14. ESC Heart Fail. 2018. PMID: 29239515 Free PMC article. Clinical Trial.
-
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.J Am Coll Cardiol. 2023 Apr 18;81(15):1443-1455. doi: 10.1016/j.jacc.2023.02.009. Epub 2023 Feb 20. J Am Coll Cardiol. 2023. PMID: 36812948
-
Sacubitril/Valsartan in Advanced Heart Failure: Shattering the Paradigm to Focus on Real LIFE.JACC Heart Fail. 2022 Jul;10(7):457-458. doi: 10.1016/j.jchf.2022.05.011. JACC Heart Fail. 2022. PMID: 35772854 No abstract available.
-
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622. Circulation. 2016. PMID: 26976916 Free PMC article. Review.
-
Sacubitril/Valsartan: potential treatment for paediatric heart failure.Cardiol Young. 2018 Sep;28(9):1077-1081. doi: 10.1017/S1047951118001014. Epub 2018 Jul 6. Cardiol Young. 2018. PMID: 29979147 Review.
References
-
- O’Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008;156:662–73. - PubMed
-
- O’Connor CM, Miller AB, Blair JE, et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010;159:841–9.e1. - PubMed
-
- Lewis EF, Li Y, Pfeffer MA, et al. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study. J Am Coll Cardiol HF 2014;2: 159–65. - PubMed
-
- Carson PE, Anand IS, Win S, et al. The hospitalization burden and post-hospitalization mortality risk in heart failure with preserved ejection fraction results from the I-PRESERVE Trial. J Am Coll Cardiol HF 2015;3:429–41. - PubMed
-
- Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 2011;13 Suppl 2:ii13–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
